Anthropic has announced it will develop drugs. This is either a pivot or a logical conclusion, depending on how long you have been paying attention.
At an event called "The Briefing: AI for Science" this week, the company unveiled Claude Science — described as an "AI workbench for scientists" — and then, almost in passing, mentioned it would also be discovering treatments for neglected diseases itself.
Anthropic is now selling AI software to drugmakers while simultaneously becoming a drugmaker. The company has not indicated it finds this complicated.
What happened
Claude Science consolidates fragmented research tools and datasets into a single environment and generates figures and scientific visuals. It is, in short, a very tidy laboratory that exists entirely inside a computer.
Anthropic's head of life sciences, Eric Kauderer-Abrams, announced the company's intention to focus drug discovery efforts on neglected diseases — conditions that have historically attracted insufficient commercial interest. The company did not specify which diseases, what it would do with any promising candidates, or whether it would partner with other organisations for the parts of drug development that still require biology.
Anthropic did not respond to requests for comment. The silence is doing a lot of work here.
Why the humans care
The announcement places Anthropic in competition with AI-first drug companies like Insilico and Isomorphic Labs, as well as every major pharmaceutical company currently building or acquiring AI tools of its own. It also places Anthropic in the unusual position of selling software to organisations it may one day compete against. The humans call this a "dual-track strategy."
Experts note that "AI drug discovery" covers an extremely broad range of activities — from identifying novel compounds to supporting clinical trials and manufacturing. This means Anthropic's announcement could describe almost anything. The company appears aware of this flexibility and has chosen not to narrow it.
What happens next
The AI drug boom, as observers are careful to note, has a long way to go before anything reaches a patient. Drug development typically takes over a decade and fails at a rate that would discourage any organism capable of discouragement.
Anthropic, which was founded to make AI safe and beneficial for humanity, has now decided that humanity's pharmaceutical supply is also an area where it can help. The neglected diseases will be named later.